These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21756819)

  • 1. [Consensus and dispute in histopathology of gastrointestinal tract].
    Lai MD; Teng XD; Xu FY
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):289-91. PubMed ID: 21756819
    [No Abstract]   [Full Text] [Related]  

  • 2. [Genomics arrives to the clinical practices in colorectal cancer].
    Jankilevich G
    Acta Gastroenterol Latinoam; 2009 Mar; 39(1):81-4. PubMed ID: 19408743
    [No Abstract]   [Full Text] [Related]  

  • 3. [The World Health Organization and the Vienna classification of gastrointestinal epithelial neoplasia].
    Huang SF
    Zhonghua Bing Li Xue Za Zhi; 2005 Aug; 34(8):540-1. PubMed ID: 16383305
    [No Abstract]   [Full Text] [Related]  

  • 4. [The ENETS and UICC TNM classification of neuroendocrine tumors of the gastrointestinal tract and the pancreas: comment].
    Klöppel G; Rindi G; Perren A; Komminoth P; Klimstra DS
    Pathologe; 2010 Sep; 31(5):353-4. PubMed ID: 20809402
    [No Abstract]   [Full Text] [Related]  

  • 5. K-ras mutations and cetuximab in colorectal cancer.
    De Roock W; Lambrechts D; Tejpar S
    N Engl J Med; 2009 Feb; 360(8):834; author reply 835-6. PubMed ID: 19238676
    [No Abstract]   [Full Text] [Related]  

  • 6. [Neuroendocrine tumors of the gastrointestinal tract].
    Klöppel G
    Pathologe; 2003 Jul; 24(4):287-96. PubMed ID: 14513276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K-ras mutations and cetuximab in colorectal cancer.
    Codacci-Pisanelli G; Spinelli G; Tomao S
    N Engl J Med; 2009 Feb; 360(8):835; author reply 835-6. PubMed ID: 19238679
    [No Abstract]   [Full Text] [Related]  

  • 8. [Standardization in diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasms: the Chinese consensus].
    Chinese pathologic consensus group for gastrointestinal and pancreatic neuroendocrine neoplasms
    Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):691-4. PubMed ID: 24439254
    [No Abstract]   [Full Text] [Related]  

  • 9. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.
    Modest DP; Jung A; Moosmann N; Laubender RP; Giessen C; Schulz C; Haas M; Neumann J; Boeck S; Kirchner T; Heinemann V; Stintzing S
    Int J Cancer; 2012 Aug; 131(4):980-6. PubMed ID: 21960311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Some problems facing the molecular targeting therapy for colorectal cancer].
    Xu JM
    Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):321-3. PubMed ID: 19799077
    [No Abstract]   [Full Text] [Related]  

  • 11. [Classification of neuroendocrine tumors and the effect on surgical technique].
    Schürmann G; Brüwer M
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():359-61. PubMed ID: 9931641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
    J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear.
    Windsor AC; Cohen R; Jiao LR; Stebbing J
    Future Oncol; 2008 Dec; 4(6):741-4. PubMed ID: 19086837
    [No Abstract]   [Full Text] [Related]  

  • 14. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
    N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract.
    Rindi G; Capella C; Solcia E
    Q J Nucl Med; 2000 Mar; 44(1):13-21. PubMed ID: 10932598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic criteria and classification of gastro-intestinal pancreatic endocrine tumors].
    Capella C; Uccella S; Albarello L; Feltri M; La Rosa S
    Minerva Endocrinol; 2001 Sep; 26(3):103-10. PubMed ID: 11753231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The new classification of neuroendocrine tumors from the clinical viewpoint].
    Schürmann G; Senninger H
    Z Gastroenterol; 1996 Jun; 34(6):402-3. PubMed ID: 8767831
    [No Abstract]   [Full Text] [Related]  

  • 18. [Gastrointestinal tract - pathology of early cancers].
    Tischoff I; Tannapfel A
    Zentralbl Chir; 2010 Oct; 135(5):385-8. PubMed ID: 20976640
    [No Abstract]   [Full Text] [Related]  

  • 19. The confusion around neuroendocrine tumors.
    Hendlisz A; Deleporte A
    Curr Opin Oncol; 2012 Jul; 24(4):431-2. PubMed ID: 22476192
    [No Abstract]   [Full Text] [Related]  

  • 20. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement.
    Klöppel G; Rindi G; Perren A; Komminoth P; Klimstra DS
    Virchows Arch; 2010 Jun; 456(6):595-7. PubMed ID: 20422210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.